HyperBio Therapeutics ApS — Credit Rating and Financial Key Figures

HyperBio Therapeutics ApS (CVR number: 41244909) is a company from VEJLE. The company recorded a gross profit of -74.5 kDKK in 2023. The operating profit was -74.5 kDKK, while net earnings were -972.7 kDKK. The profitability of the company measured by Return on Assets (ROA) was 0.5 %, which can be considered weak but Return on Equity (ROE) was -11.9 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at 5 %, a level that can be considered to be very low. This means the company is highly leveraged, with most assets financed through debt. This high level of financial risk could pose challenges in periods of financial distress or rising interest rates. HyperBio Therapeutics ApS's liquidity measured by quick ratio was 1.1 which is at a modest level. Thus, the company's liquid assets are in relative balance with its short-term liabilities, indicating a moderate liquidity position. While it's likely to meet its current obligations, financial flexibility may be constrained, and unexpected costs could pose challenges.